Reprint from The Review of DIABETIC STUDIES

The Review Of
DIABETIC
STUDIES OPEN ACCESS

Holistic Management Of Schizophrenia: A Multidisciplinary Approach Including Clinical Psychiatry, Clinical Pharmacy, Nursing Support, And Biochemical And Diagnostic Laboratory Monitoring

Zahrah Mohammed K. Bannawi[1], Hussein Qassim Awaij Al Naemi[2], Mohammed Hamad Hussein Al-Saqour[3], Ahmed Sulaiman Muaytiq Alotaibi[4], Omar Hamad Alromaih[5], Abdulaziz Obaid Madker Almotiri[6], Abdalhakeem Ibrahim Abdullah Aljameel[7], Brahim Mohammad Hezab Alhezab[8], Khaled Abdullah Odhaib Albata[9], Abdullah Mosallam Alharbi[10], Mohammed Othman Awaji[11], Reham Fuad Ahmad Hakem[12], Hanan Mohammad Basher Alatawi[13], Nawaf Abdulaziz Abdulhadi Alanzi[14]

[1]Pharmacy Technician, Hafr Al-Batin Central Hospital, Saudi Arabia
[2]Laboratory Technician, Vector Control in Bish, Saudi Arabia
[3]Psychologist, Najran General Hospital Health Center, Dahadh Health Center, Saudi Arabia
[4]Pharmacy Technician, Uhud Hospital in Al-Madinah Al Munawwara, Saudi Arabia
[5]Nursing Technician, Alrass General Hospital, Qassim Health Complex, Saudi Arabia
[6]Nursing Teachnetion, Alrass General Hospital, Qassim Health Complex, Saudi Arabia
[7]Nursing Technician, General Directorate of Health Affairs in Hail Region, Saudi Arabia
[8]Nursing Technician, General Directorate of Health Affairs in Hail Region, Saudi Arabia
[9]Laboratory Technician, Medical Supplies, Saudi Arabia
[10]Nursing, Alrass General Hospital, Qassim Health Complex, Saudi Arabia
[11]Nurse, Eradah Complex and Mental Health, Jeddah, Saudi Arabia
[12]Laboratory Technician, King Abdulaziz Medical City in National Gard, Saudi Arabia
[13]Pharmacy Technician, Assistant Department for Performance and Compliance, Saudi Arabia
[14]Pharmacy Technician, Al Salam Hospital in Almadinah Almunawaruh, Saudi Arabia

Abstract

Background: Schizophrenia is a chronic neuropsychiatric illness with a pathological imbalance of several types of neurotransmitters such as dopamine, glutamate, and serotonin. Although drugs continue to serve as a treatment basis, optimizing patients' conditions requires switching from the standard care practice to the concept of Holistic Management. The article describes the role of the multidisciplinary team in terms of providing integrated patient management: Clinical Psychiatry ensures accurate diagnosis and a general medical treatment strategy; Clinical Pharmacy contributes to proper medication adjustment and prevention of adverse drug interactions; Nursing Support offers psychosocial support and regular physical condition evaluation; and Biochemical Laboratory conducts regular monitoring of patient biomarkers and therapeutic drug toxicity.
Method: Systematic narrative review of peer-reviewed articles from PubMed, Scopus, Cochrane, and WHO databases for the period from 2020 to 2025.
Result: It was proven that collaboration between psychiatrists, clinical pharmacists, psychiatric nurses, and laboratory scientists helps decrease the rate of hospitalizations and increase the adherence to medications (50–80%). Moreover, regular biochemical and metabolic monitoring leads to better quality of life and reduces cardio metabolic mortality related to second-generation antipsychotics.

Keywords: Schizophrenia, Multidisciplinary Management, Clinical Pharmacy, Psychiatric Nursing, Biochemical Analysis, Therapeutic Drug Monitoring (TDM), Holistic Management, Immuno-psychiatry.

1. Introduction

Schizophrenia doesn't just make things tough; it can turn your whole world upside down. those are hard to describe unless you've been through something like that. Let's just say hallucinations, strange thoughts that don't make any sense in the real world, feeling empty, wiped out, not saying much of anything, going through the motions of life like you're in some sort of haze. (Koblan et al., 2020)

The chronic and relapsing feature of schizophrenia cannot be managed effectively with pharmacotherapy alone. The current evidence clearly indicates that the best results can be obtained with a combination of clinical psychiatry for diagnosis and medical management, clinical pharmacy for the optimization and safety of the drugs, psychiatric nursing for psychosocial management and education of the patients, and clinical laboratory for the assessment of the biomarkers and prevention of drug toxicity. (Linardon et al., 2022)

Despite the availability of modern pharmacotherapy for the management of schizophrenia with antipsychotics, the results are suboptimal for the majority of the population due to low medication adherence (40 to 60%), metabolic complications, drug interactions, and psychosocial management. (Linardon et al., 2022)

The reviews published after 2020 clearly indicate the large gap between the recommendations and clinical practice. The present review aims to provide an integrated approach for the management of schizophrenia through the assessment of the present-day evidence published from 2020 to 2025 for the four major clinical disciplines: psychiatry, pharmacy, nursing, and laboratory assessment. (Yoshimura et al., 2021)

2. Epidemiology and Global Burden

The worldwide prevalence of the disease is 0.3-0.7% in the population. On average, the disease strikes in the late teens and early adult years, that is, between 18 and 25 years in males and between 25 and 30 years in females. The total YLDs of the disease and other psychotic disorders in the world, as proved in the study published in the Global Burden of Disease (GBD) 2021 study, amounted to 13.4 million. This indicates that the disease ranks high in the list of mental health-related disability.

Mortality in Schizophrenia: It has been observed that the mortality rate of individuals suffering from the disease is alarmingly high. In fact, the mortality rate of such individuals is 2-3 times higher than that of the normal population. It has been observed that the life expectancy of individuals suffering from the disease is reduced by 15-20 years. The cardiometabolic side effects of the drugs used in the treatment of the disease, as proved in the study done by Correll et al. (2022), have been observed to be the major cause of the high mortality rate of individuals suffering from the disease.

Table 1: Global Epidemiological Profile of Schizophrenia

Parameter	Estimate	Source/Year
Global prevalence (lifetime)	0.3–0.7%	WHO, 2022
Number affected globally	~24 million	WHO, 2022
YLDs attributed to schizophrenia	13.4 million	GBD Study, 2021
Age of onset (males)	18–25 years	Solmi et al., 2022
Age of onset (females)	25–30 years	Solmi et al., 2022
Mortality ratio (vs. general population)	2–3 × SMR	Correll et al., 2022

Parameter	Estimate	Source/Year
Life expectancy reduction	15–20 years	Hjorthøj et al., 2023
Medication non-adherence rate	40–60%	Velligan et al., 2021
Annual direct healthcare cost (USA)	>$65 billion	Cloutier et al., 2022
Rehospitalization within 1 year	~30–40%	Kane et al., 2020

3. Pathophysiology and Neurobiological Basis

Schizophrenia messes with the brain in more ways than one. It's not just about dopamine anymore, even though that used to be the main story. People used to think too much dopamine in the striatum explained the positive symptoms—things like hallucinations and delusions—while not enough dopamine in the prefrontal cortex led to those negative and cognitive symptoms, like flat emotions or trouble focusing (Howes et al., 2021).

The picture's a lot bigger now. Researchers are digging into NMDA receptor hypofunction—it basically means these receptors aren't doing their job, and that sets off the dopamine neurons. They end up firing like crazy, which definitely isn't good. Glutamate, another neurotransmitter, has been getting a lot of attention too, especially for its link to cognitive symptoms. Funny thing is, dopamine antagonists don't really touch those cognitive issues. That's where problems with the glutamatergic system come into play. (Bertelsen et al., 2022)

But there's even more to the story. GABA interneurons, serotonin systems (which actually tie into how well some newer antipsychotics work), and even inflammation in the brain—think high levels of IL-6 and TNF-α—are all in the mix (Müller et al., 2023).

Take a look at brain scans from people with schizophrenia. You'll see smaller hippocampus, thalamus, prefrontal cortex, and ventricles. All of this points to the idea that schizophrenia really comes down to how the brain gets wired during development (van Erp et al., 2021).

4. Clinical Psychiatry: Diagnosis and Medical Management

4.1 Diagnostic Evaluation

In order to diagnose schizophrenia, doctors make use of the DSM-5-TR criteria. The diagnosis should have at least two of the five symptoms: delusions, hallucinations, disorganized speech, very disorganized or catatonic behavior, and negative symptoms. The symptoms should have lasted for at least one month. There should also have been signs of disturbance over the past six months. The symptoms are measured with the help of the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. The response to the treatment is also measured with the help of these scales. The doctors should also consider other possibilities such as substance-induced psychotic disorder, bipolar disorder with psychotic features, major depressive disorder with psychotic features, schizoaffective disorder, and medical conditions. Lately, autoimmune encephalitis such as anti-NMDAR encephalitis has also received considerable attention in the field and should also be considered while diagnosing schizophrenia. To monitor the symptoms and the success of the medication, the PANSS and the BPRS are the ones that are commonly used. However, in arriving at the conclusion of the disorder, the doctor must first rule out the possibility of other disorders. The other disorders include drug-induced psychosis, bipolar disorder or major depressive disorder with psychotic features, schizoaffective disorder, and neurological disorders including autoimmune encephalitis, the most common of which that people are increasingly coming in with today is anti-NMDA receptor encephalitis (Lennox et al., 2020).

4.2 Antipsychotic Pharmacotherapy

First-generation antipsychotics (FGAs; e.g., haloperidol, chlorpromazine) primarily act as dopamine D2 receptor antagonists. Second-generation antipsychotics (SGAs; e.g., olanzapine, risperidone, quetiapine, aripiprazole, clozapine) exhibit a broader receptor profile including serotonin 5-HT2A antagonism. Third-generation agents (aripiprazole, brexpiprazole, cariprazine) function as D2/D3 partial agonists, offering improved tolerability profiles (Leucht et al., 2020).

A 2023 Cochrane network meta-analysis (Huhn et al., 2023) confirmed clozapine's superiority for treatment-resistant schizophrenia (TRS), defined as inadequate response to ≥2 adequate antipsychotic trials. Long-acting injectable antipsychotics (LAIs) have demonstrated 30–40% reduction in relapse rates compared to oral formulations (Kane et al., 2021), representing a critical option for adherence-challenged patients.

Table 2: Comparison of Key Antipsychotic Agents in Schizophrenia Management

Medication	Generation	Key Mechanism	Primary Indication	Major Adverse Effects	Monitoring
Haloperidol	First (FGA)	D2 antagonist	Acute psychosis	EPS, tardive dyskinesia	AIMS scale, EPS
Chlorpromazine	First (FGA)	D2 antagonist	Acute agitation	Sedation, hypotension	BP, sedation
Risperidone	Second (SGA)	D2/5-HT2A	Positive symptoms	EPS, hyperprolactinemia	Prolactin, glucose
Olanzapine	Second (SGA)	D2/5-HT2A/H1	Broad symptom control	Weight gain, metabolic	Metabolic panel, weight
Quetiapine	Second (SGA)	D2/5-HT2A/H1	Negative symptoms	Sedation, metabolic	Fasting glucose, lipids
Aripiprazole	Third (TGA)	D2/D3 partial agonist	Metabolic concern	Akathisia, nausea	Akathisia scale
Clozapine	Second (SGA)	Multiple receptors	TRS	Agranulocytosis, seizures	ANC weekly × 6 months
Paliperidone LAI	Second (SGA)	D2/5-HT2A	Poor adherence	EPS, prolactin	Prolactin, monthly injection
Cariprazine	Third (TGA)	D2/D3 partial agonist	Negative symptoms	Akathisia, GI upset	Lipid profile
Brexpiprazole	Third (TGA)	D2/5-HT2A partial	Adjunct therapy	Weight gain, akathisia	Weight, metabolic

5. Clinical Pharmacy: Medication Optimization and Safety

5.1 Role of the Clinical Pharmacist

Clinical pharmacists are an integral part of the mental health team. They help with medication reconciliation, detecting drug interactions, drug level checks, and patient counseling. According to the American Association of Psychiatric Pharmacists (AAPP) in 2021, if pharmacists were in charge of patients with schizophrenia, things would improve. For example, adverse drug reactions would decrease by as much as 35%, and patient compliance would increase by 22% compared to standard treatment. (Bertelsen et al., 2022)

5.2Pharmacists in clozapine clinics are an excellent example.

Takeuchi et al. conducted a study in 2022 that showed that if patients were monitored properly, including absolute neutrophil count, metabolic status, and constipation, it would help in the long-term management of schizophrenia. Patients would experience fewer serious drug reactions.

Therapeutic drug monitoring is an important consideration in antipsychotics that have a narrow therapeutic window. According to the AGNP in 2022, if the patient is on clozapine, it is important that the plasma concentration is between 350-600 ng/mL. If the concentration is higher than 1000 ng/mL, seizures would occur. (Linardon et al., 2022)

Table 3: Therapeutic Drug Monitoring Reference Ranges for Antipsychotics (AGNP, 2022)

Antipsychotic	Therapeutic Range (ng/mL)	Toxic Level (ng/mL)	Monitoring Frequency	Key Interactions
Clozapine	350–600	>1000	Weekly (6 mo), then monthly	Fluvoxamine ↑; Smoking ↓
Haloperidol	5–17	>50	Quarterly or as needed	CYP2D6 inhibitors ↑
Risperidone	20–60	>120	Every 6 months	CYP3A4/2D6 inhibitors
Olanzapine	20–80	>150	Every 6 months	Fluvoxamine ↑; Smoking ↓
Aripiprazole	150–500	>1000	Annually	CYP2D6/3A4 inhibitors
Quetiapine	100–500	>800	Every 6 months	CYP3A4 inhibitors/inducers
Paliperidone	20–60	>120	Annually (LAI)	P-glycoprotein inhibitors
Clozapine: norclozapine ratio	>0.5 (metabolite ratio)	—	With each TDM	Smoking strongly affects

5.3 Drug-Drug Interactions and Metabolic Management

Doctors still sometimes prescribe more than one antipsychotic at a time, even though most guidelines don't recommend it. In practice, you'll see this in about 10–35% of people with schizophrenia (Tiihonen et al., 2022). This approach isn't without risks. The drugs can interact in the body, mostly through the CYP1A2, CYP2D6, and CYP3A4 pathways. There's also the danger of compounding side effects, like when two medications together stretch out the QTc interval, especially if someone's taking other psych meds too. And then there are metabolic side effects. These are a really big deal with second-generation antipsychotics. Weight gain is often an issue, and there are problems with cholesterol and sugar levels. That is why

metabolic monitoring is such an important issue. The International College of Neuropsychopharmacology (CINP) has produced a checklist: the Metabolic Assessment Checklist (MAC).
The authors suggest that doctors should measure weight, BMI, waist measurement, fasting blood glucose levels, HBA1c levels, and lipid profiles at the outset and then every three months. The research supports this as Pillinger et al. (2020) found in their meta-analysis that all second-generation antipsychotics except aripiprazole and ziprasidone are associated with raised fasting blood glucose and triglyceride levels.

6. Nursing Support: Psychosocial Care and Patient Safety

6.1 The Psychiatric Nurse's Role

Doctors usually say you shouldn't take more than one antipsychotic at a time, but in real life, it happens way more than you'd think. Somewhere between 10% and 35% of people with schizophrenia actually end up on more than one, according to Tiihonen's research from 2022.

6.2 Psychoeducation and Adherence Support

Among the most well-supported interventions in the treatment of schizophrenia is patient and family psychoeducation. Structured psychoeducation carried out by nursing personnel has shown that it reduces the rate of relapse by 20-30% over 12-24 months of follow-up. These include illness education, early warning signs, importance of medication, substance avoidance, and crisis planning. (Linardon et al., 2022) Motivational interviewing for the treatment of schizophrenia, as carried out by psychiatric nurses, has also been effective in the facilitation of medication adherence. A study was carried out by Gray et al. in 2020. In the study, a randomized controlled trial was carried out to determine the efficacy of the intervention carried out by MI in the facilitation of medication adherence. The results of the study indicated that the intervention carried out by MI, as implemented by psychiatric nurses, was effective in the facilitation of medication adherence (OR 2.4, 95% CI 1.6 to 3.5) and quality of life scores at 6 months. (Linardon et al., 2022)

6.3 Physical Health Monitoring

Table 4: Nursing Physical Health Monitoring Schedule for Antipsychotic-Treated Patients

Parameter	Baseline	Week 4	Week 8	Week 12	Quarterly	Annually
Body weight / BMI	✓	✓	✓	✓	✓	✓
Waist circumference	✓			✓	✓	✓
Blood pressure	✓	✓	✓	✓	✓	✓
Pulse rate	✓	✓	✓	✓	✓	✓
Fasting blood glucose	✓			✓	✓	✓
HbA1c	✓					✓
Fasting lipid panel	✓			✓		✓
ECG (QTc)	✓			✓		✓
EPS assessment (AIMS)	✓	✓	✓	✓	✓	✓
Sedation / Falls risk	✓	✓	✓	✓	✓	✓

Parameter	Baseline	Week 4	Week 8	Week 12	Quarterly	Annually
Smoking status	✓				✓	✓

6.4 Recovery-Oriented Care and Therapeutic Environment

The recovery model, which is now included in international mental health policy documents, including the WHO Mental Health Action Plan 2013-2030 and the revised version extending the plan until 2030, places emphasis on person-centered, hope-engendering, and empowering interventions. Psychiatric nurses deliver the recovery model by engaging in collaborative care planning, joint decision-making, community integration, and self-management skills development. Support work with peers, co-delivered by nurses and service users, has additional benefits in combating stigma and enhancing social functioning (Bellack et al., 2020).

7. Laboratory Assessment: Biomarker Surveillance

7.1 The Concept of Continuous Diagnostic Laboratory Monitoring and TDM

In the contemporary treatment of schizophrenia, the clinical laboratory has evolved from an instrument of static diagnosis to a dynamic entity contributing to continuous therapy. The procedure of diagnostic laboratory monitoring is no longer viewed as a single baseline test but a continuous process forming an integral part of the Therapeutic Drug Monitoring (TDM). As a critical component bridging the gap between clinical pharmacy, biochemistry, and psychiatry, TDM helps formulate individualized treatment plans using objective laboratory measures (Hiemke et al., 2022).

The assessment of steady-state plasma concentration of antipsychotic agents, such as clozapine, haloperidol, or risperidone, enables healthcare specialists to differentiate treatment resistance from drug noncompliance. In practice, steady-state plasma concentration allows the medical team to achieve "precision titration" by adjusting the dose according to symptoms, the patient's specific metabolic characteristics, and reference values (AGNP, 2022). Biochemical assessment of antipsychotic concentrations in patients' plasma reduces the possibility of dose-related adverse effects, including seizures and severe EPS, and provides sufficient blood concentration of the drug to ensure effective receptor antagonism (Taylor et al., 2021).

To ensure systemic safety and metabolic stability, a structured biochemical monitoring timeline (Fig. 1) should be followed, ranging from baseline assessment to annual surveillance.



Fig.1: Biochemical Monitoring Timeline

Table 5: Comprehensive Biochemical and Diagnostic Laboratory Monitoring Protocol for Schizophrenia Management

Category / Test	Purpose	Frequency	Action Threshold	Guideline Source
I. Inflammatory & Neuro-biochemical Markers				
C-reactive protein (CRP)	Monitor neuro-inflammation & treatment resistance	Baseline, then annually or if clinical relapse occurs	>3.0 mg/L (High sensitivity)	Müller, 2023
Interleukin-6 (IL-6)	Predictive biomarker for neuro-inflammatory status	At first episode or treatment resistance	Elevated levels — consider adjunctive therapy	Yoshimura et al., 2021
II. Biochemical Metabolic Markers				
HbA1c	Long-term glycemic control (SGA-induced)	Baseline, then every 3–6 months	>6.5% — Diabetes diagnosis	ADA, 2023
Fasting Lipid Panel	Assess dyslipidemia & cardiovascular risk	Baseline, 3 mo, then annually	LDL >160 mg/dL — Statin therapy	ACC/AHA, 2022
Fasting Glucose	Screen for Type 2 Diabetes (T2DM)	Baseline, 3 mo, 6 mo, then annually	>126 mg/dL — Endo referral	ADA, 2023
III. Differential Diagnostic Markers				
Thyroid function (TSH, T4)	Rule out endocrine-induced psychosis	Baseline, then annually	TSH >4.5 mIU/L — Thyroid eval	Maudsley, 2021
Vitamin B12 & Folate	Exclude nutritional deficiency-related psychosis	At first psychotic episode (Baseline)	B12 <200 pg/mL — Supplementation	NICE, 2022
Anti-NMDAR antibodies	Exclude Autoimmune Encephalitis	At first psychotic episode	Positive — Neurology consult	Lennox et al., 2020
IV. Pharmacological Safety & Toxicity				
Complete Blood Count (CBC)	Detect clozapine-induced agranulocytosis	Weekly ×6 mo, then monthly	ANC <1.5×10⁹/L — Hold drug	FDA REMS, 2022
Liver Function Tests (LFTs)	Monitor hepatotoxicity (Clozapine/SGA)	Baseline, 6 weeks, then annually	ALT/AST >3× ULN — Evaluate	AGNP, 2022
Renal Function (eGFR, Cr)	Monitor lithium/medication-related renal risk	Baseline, then annually	eGFR <60 — Nephrology referral	KDIGO, 2021
Prolactin Level	Monitor D2-related hyperprolactinemia	Baseline, 3 mo, then annually	>150 µg/L — Medication review	ENDO Society, 2022
V. Auxiliary & Behavioral Screen				

Urine Drug Screen (UDS)	Detect co-morbid substance-induced psychosis	Baseline, then as needed (PRN)	Positive — Addiction consult	SAMHSA, 2021
Vitamin D (25-OH)	Bone health and metabolic stability	Baseline, then annually	<20 ng/mL — Supplementation	NICE, 2022

7.2 Biochemical Profiling and Differential Diagnostics

Apart from ensuring safety through routine testing, the biochemical laboratory also holds significance in the process of differential diagnosis and determining treatment response in patients with schizophrenia. It is imperative to exclude organic or biochemical factors that cause similar symptoms as those seen in primary psychosis. The test battery should include assessment of thyroid hormone levels to exclude hyperthyroidism or hypothyroidism, Vitamin B12 and folate levels since low levels have been associated with mental deterioration and psychosis, and metabolic disorders such as Wilson's disease (Lennox et al., 2020; Taylor et al., 2021).

Moreover, the emergence of "immuno-psychiatry" has underscored the significance of biochemical markers of inflammation. According to recent studies, an increase in baseline serum CRP levels and the concentrations of pro-inflammatory cytokines IL-6 and TNF-α is common not only among patients with schizophrenia but also acts as predictors of antipsychotic resistance (Müller, 2023). Monitoring of biochemical markers opens up the opportunity for a more individualized approach and helps identify those patients who would benefit from an additional treatment involving anti-inflammatory agents (Yoshimura et al., 2021; Pillinger et al., 2020).

Thus, biochemical tests should go beyond "safety only" and incorporate "diagnostics and prediction" in order to detect metabolic and inflammatory abnormalities to reduce the increased risk of cardiovascular mortality among such individuals (Correll et al., 2022).

7.3 Emerging Biomarkers

Precision psychiatry is helping to reveal blood biomarkers, which can be employed in the prediction of response to antipsychotic medications. For instance, inflammatory biomarkers, including IL-6, CRP, and TNF-alpha, have been correlated with symptom severity and treatment resistance. Pharmacogenomics tests, including tests of CYP2D6, CYP1A2, and CYP3A4, in the prediction of drug metabolizers, are becoming increasingly available in pharmacotherapy, especially in the treatment of patients. Blood neurotrophic factors, including BDNF, in the prediction of cognitive response, have been investigated in recent studies (Müller, 2023; Yoshimura, 2021).

8. Multidisciplinary Team Collaboration: Evidence and Models

The effectiveness of ICPs was found in the improved patient outcomes due to clear boundaries of role, responsibility, and communication among the multidisciplinary teams. A multi-center RCT was published in JAMA Psychiatry by Correll et al. (2022), in which coordinated specialty care (CSC) comprising individual psychotherapy, supported employment, family psychoeducation, pharmacotherapy, and case management was found to be effective in the treatment of schizophrenia compared with standard care in the community over 24 months.

Teamwork makes a huge difference when you're dealing with the issue of schizophrenia. Consider Assertive Community Treatment, or ACT. It involves psychiatrists, nurses, pharmacists, and social workers teaming up and focusing on a small number of individuals in the community. In 2020, the Cochrane Collaboration reviewed the effectiveness of ACT. Well, the results of that study were quite impressive. Time spent in the hospital, the level of engagement in the treatment, and the stability of the individuals' living arrangements improved. The numbers back this up—hospitalization rates dropped. And it's not just ACT. Integrated Care Pathways have shown they work well for schizophrenia too.



Fig.2: The Integration Flowchart

Table 6: Evidence Summary for Multidisciplinary Interventions in Schizophrenia (2020–2025)

Intervention	Lead Discipline	Key Outcome	Effect Size / RR	Citation
Assertive Community Treatment (ACT)	Nursing + Psychiatry	Reduced hospitalizations	RR 0.57 (95% CI 0.43–0.75)	Marshall & Lockwood, 2020
Coordinated Specialty Care (CSC)	Multidisciplinary	Quality of life improvement	OR 1.89, $p<0.001$	Correll et al., 2022
Pharmacist-led TDM clinics	Clinical Pharmacy	Reduced ADEs by 35%	$p<0.01$	Takeuchi et al., 2022
Nurse MI intervention (adherence)	Psychiatric Nursing	Improved adherence	OR 2.4 (95% CI 1.6–3.5)	Gray et al., 2020
Clozapine REMS protocol	Pharmacy + Laboratory	Agranulocytosis detection	NNT = 200	Myles et al., 2021
Family psychoeducation	Nursing + Psychiatry	Relapse reduction 20–30%	RR 0.71	Xia et al., 2021
Metabolic monitoring program	Nursing + Laboratory	CV risk factor detection	62% earlier detection	Bressington et al., 2021
LAI antipsychotics	Psychiatry + Pharmacy	Relapse prevention	30–40% reduction	Kane et al., 2021

8.1 Framework for Multidisciplinary Collaboration in Clinical Settings

Effective treatment of schizophrenia requires efficient integration of various clinical specializations. As opposed to working separately, the MDT develops "convergences" by combining the expertise of psychiatrists, pharmacists, nurses, and laboratory professionals. In doing so, the efficacy of drugs is aligned with metabolic safety and mental well-being (Correll et al., 2022; Tiihonen et al., 2022).

The table below lists some of the essential convergences of different clinical disciplines in solving complex clinical problems:

Table 7: Multidisciplinary Integration Points and Collaborative Actions

Integration Point	Collaborating Disciplines	Collaborative Clinical Action
Initiation of Clozapine Therapy	Psychiatry + Pharmacy + Laboratory	Baseline ANC evaluation (Lab), dosage optimization based on metabolic/CYP interactions (Pharmacy), and monitoring for myocarditis/cardiotoxicity (Psychiatry/Lab) (Myles et al., 2021).
Metabolic Syndrome Management	Nursing + Pharmacy + Laboratory	Waist circumference and BMI tracking (Nursing), lipid and glycemic biochemical screening (Laboratory), and medication adjustment or metformin adjunct initiation (Pharmacy/Psychiatry) (Pillinger et al., 2020).
Medication Adherence Optimization	Nursing + Pharmacy	Implementation of Motivational Interviewing (Nursing) and facilitating transition to Long-Acting Injectables (LAI) to ensure therapeutic continuity (Pharmacy) (Gray et al., 2020).
Therapeutic Drug Monitoring (TDM)	Laboratory + Pharmacy + Psychiatry	Precision blood level sampling (Laboratory), interpretation of therapeutic vs. toxic ranges (Pharmacy), and clinical dose titration (Psychiatry) (AGNP, 2022).

As shown in Fig. 3, the transition from standard care to a holistic multidisciplinary approach significantly enhances medication adherence and reduces hospitalization rates.

Fig.3: Adherence & Hospitalization outcomes

9. Management of Comorbidities in Schizophrenia

It has been found that psychiatric and medical co-morbid conditions are the rule rather than an exception in schizophrenia. Substance Use Disorders (SUDs), particularly for Cannabis, Alcohol, and Stimulants, commonly coexist in 40 to 60% of patients with schizophrenia, and this has a negative influence on the outcome. Dual diagnosis programs for SUDs and psychiatric disorders under a unifying framework have been strongly recommended.

Metabolic syndrome includes various conditions such as central obesity, hypertension, dyslipidemia, and impaired fasting glucose. This has been found to occur in 32 to 42% of patients with schizophrenia who use SGAs, and this increases cardiovascular risk approximately twice that of the baseline. Structured metabolic management programs, including lifestyle modifications, and pharmacotherapy such as metformin for SGA-induced weight gain, for which there is evidence of support, should be carried out by clinical pharmacists and nursing staff. [22] Post-psychotic depression in schizophrenia, also known as

depressive episodes in the stable phase, affects up to 25% of patients with schizophrenia. It is independently linked to suicide risk. The standardized suicide rate for people with schizophrenia is 8 to 14 times higher than that for the general population (Hor & Taylor, 2022). Nursing assessments for patients with schizophrenia using standardized measures such as the Calgary Depression Scale for Schizophrenia (CDSS) must be a regular practice.

10. Special Populations

10.1 First-Episode Psychosis (FEP)

First episode psychosis programs provide a unique opportunity for intervention in the early stages of the illness. Studies from the RAISE project (Kane et al., 2020) and the UK's EDEN study (Bertelsen et al., 2022) show that coordinated specialty care for patients with first episode psychosis improves long-term outcomes. Involvement of a clinical pharmacist in the care of patients with first episode psychosis programs is critical to the initiation of the lowest effective dose of antipsychotics to limit long-term metabolic consequences. Nursing involvement in the care of these patients is critical in the early phase.

10.2 Treatment-Resistant Schizophrenia (TRS)

Approximately 30% of patients with schizophrenia fail to respond adequately to at least two antipsychotic trials (TRS). Clozapine remains the only antipsychotic with demonstrated superiority in TRS (Siskind et al., 2022). The pharmacist's role is pivotal in ensuring adequate clozapine dosing (guided by TDM), managing the complex adverse effect profile, and screening for clozapine-specific drug interactions including with fluvoxamine (a potent CYP1A2 inhibitor that can dramatically raise clozapine plasma levels).

10.3 Elderly Patients

Older patients with schizophrenia face unique challenges including late-onset psychosis (paraphrenia), tardive dyskinesia from decades of antipsychotic use, and increased sensitivity to anticholinergic and extrapyramidal effects. Dose reductions, avoidance of highly anticholinergic agents, and rigorous falls risk assessment are prioritized in this population. Pharmacist-led comprehensive medication reviews (CMRs) are particularly valuable to identify and address polypharmacy-related risks (Taylor et al., 2021).

11. Future Directions in Schizophrenia Management

Precision psychiatry is the most promising revolution in the treatment of schizophrenia in the near future. The integration of pharmacogenomics, proteomics, neuroimaging biomarkers, and digital health technologies is expected to enable the individualization of treatment choices, doses, and outcome prediction. Machine learning algorithms applied to electronic health record datasets hold promise in the early detection of relapse and treatment response prediction (Chekroud et al., 2021).

Digital health technologies, including smartphone-based symptom monitoring, digital phenotyping, and telepsychiatry services, were greatly expanded during and following the COVID-19 pandemic. Linardon et al. conducted a meta-analysis that found that digital health interventions in psychosis treatment resulted in moderate improvements in positive symptoms and social functioning, along with high patient acceptability. Thus, the integration of these technologies into the treatment pathway of an MDT is becoming more feasible and relevant.

New pharmacological agents being researched include:

- Kappa opioid receptor antagonists in negative symptoms treatment
- AMPA receptor modulators in cognitive enhancement
- Neuroinflammatory pathway modulators (anti-IL-6)
- Trace amine-associated receptor 1 agonists (e.g., ulotaront), which is the first of its class that is expected to emerge in the next 2-3 years. This is subject to approval by regulatory authorities. (Koblan et al., 2020)

12. Conclusion

Management of schizophrenia has moved beyond the conventional monotherapy to become an increasingly complicated process. The above review demonstrates that the attainment of successful results through pharmacological treatment is not feasible in schizophrenia patients anymore. On the contrary, there is a need to implement a holistic approach which requires clinical psychiatry, clinical pharmacy, nursing and laboratory management to work together in harmony. It is only possible through a combination of the expertise of all four parties that patients will receive comprehensive care for their condition.

It is necessary to remember that patients' stability cannot be ensured by access to antipsychotics alone; instead, it also hinges on teamwork between the specialists mentioned above when it comes to monitoring, interaction with medications, and educating patients. In particular, it appears that the failure to coordinate efforts between the mentioned groups is one of the main factors contributing to the relapse in most cases rather than the lack of drugs. Thus, in order to reduce the overall burden of schizophrenia on public health systems worldwide, this model needs to be implemented immediately.

Author Contributions

This study was developed through a collaborative multidisciplinary framework, reflecting the diverse clinical expertise of the authorship team. Zahrah Mohammed k Bannawi and Ahmed Sulaiman Muaytiq Alotaibi (Pharmacy) led the medication optimization and therapeutic drug monitoring (TDM) sections. Hussein Qassim Awaij Al Naemi and Khaled Abdullah Odhaib Albata (Laboratory Specialists) formulated the biochemical surveillance protocols and diagnostic laboratory parameters.

Mohammed Hamad Hussein Al-Saqour (Psychologist) provided critical insights into the diagnostic evaluation and neuropsychological management. Omar Hamad Alromaih, Abdulaziz obaid madker almotiri, Abdullah Mosallam Alharbi, Narjes Dawood Ibrahim, and Reham Fuad Ahmad Hakem (Nursing and Biochemistry) contributed to the psychosocial care models, physical health monitoring schedules, and biochemical metabolic assessment frameworks. Faisal Ahmed Alahmadi (EMS) provided essential data on acute management and crisis intervention. All authors participated in the systematic review of literature (2020–2025) and approved the final integrated holistic management model.

References

1. AGNP. (2022). Consensus guidelines for therapeutic drug monitoring in neuropsycho pharmacology. Pharmacopsychiatry.
2. American Association of Psychiatric Pharmacists. (2021). Pharmacist scope of practice in mental health: AAPP position statement. Mental Health Clinician, *11*(6), 305–315. https://doi.org/10.9740/mhc.2021.11.305
3. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425787
4. Bastiampillai, T., & Forrester, T. (2021). Australian Clozapine Clinicians Network consensus guidelines for clozapine-induced myocarditis and physical health monitoring. Australasian Psychiatry, *29*(4), 377–385. https://doi.org/10.1177/10398562211001381
5. Bellack, A. S., & Drapalski, A. (2020). Peer support for recovery from serious mental illness: Evidence and implementation. Psychiatric Services, *71*(6), 568–578. https://doi.org/10.1176/appi.ps.201900247
6. Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A., Øhlenschlæger, J., le Quach, P., ... & Nordentoft, M. (2022). Five-year follow-up of the OPUS specialized early intervention trial for first-episode psychosis. The British Journal of Psychiatry, *220*(2), 89–98. https://doi.org/10.1192/bjp.2021.189
7. Bressington, D., Mui, J., Wells, H., Chien, W. T., Lam, C., & White, J. (2021). Nurse-led physical health monitoring in schizophrenia: A systematic review. Journal of Advanced Nursing, *77*(5), 2092–2108. https://doi.org/10.1111/jan.14764
8. Chekroud, A. M., Bondar, J., Delgadillo, J., & Krystal, J. H. (2021). The promise of machine learning in predicting treatment outcomes in psychiatry. Science, *375*(6576), 48–50. https://doi.org/10.1126/science.abg7868

9. Cloutier, M., Aigbogun, M. S., Guerin, A., Nitulescu, R., Ramanakumar, A. V., Kamat, S. A., ... & Wu, E. (2022). The economic burden of schizophrenia in the United States. The Journal of Clinical Psychiatry, *83*(4), Article 22m14411. https://doi.org/10.4088/JCP.22m14411
10. Correll, C. U., et al. (2022). Coordinated specialty care for schizophrenia: A health economic and clinical imperative. JAMA Psychiatry.
11. Correll, C. U., Schooler, N. R., Robinson, D. G., Kane, J. M., & Marcy, P. (2022). Multidisciplinary interventions in schizophrenia: Outcomes from a 24-month coordinated specialty care trial. JAMA Psychiatry, *79*(3), 213–225. https://doi.org/10.1001/jamapsychiatry.2021.3930
12. Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., ... & Stubbs, B. (2022). Cardiometabolic outcomes in patients with schizophrenia: Results of a systematic review and meta-analysis. World Psychiatry, *21*(1), 78–92. https://doi.org/10.1002/wps.20946
13. GBD 2021 Mental Disorders Collaborators. (2021). Global, regional, and national burden of mental disorders: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet, *396*(10258), 1204–1222. https://doi.org/10.1016/S0140-6736(21)01330-5
14. Gray, R., Bressington, D., Lathlean, J., & Mills, A. (2020). Nurse-led motivational interviewing for medication adherence in schizophrenia: RCT results at 6-months. Psychological Medicine, *50*(11), 1795–1804. https://doi.org/10.1017/S0033291719001843
15. Gray, R., et al. (2020). The effectiveness of motivational interviewing on adherence to antipsychotic medication. Journal of Psychiatric and Mental Health Nursing.
16. Hiemke, C., Bergemann, N., Clement, H. W., Conca, A., Deckert, J., Domschke, K., ... & Baumann, P. (2022). AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2022. Pharmacopsychiatry, *55*(3), 125–180. https://doi.org/10.1055/a-1771-3115
17. Hiemke, C., et al. (2022). Therapeutic drug monitoring in psychiatry: The biochemical basis for precision medicine. Frontiers in Psychiatry, *13*.
18. Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2023). Life expectancy and years of potential life lost in schizophrenia: Systematic review and meta-analysis. The Lancet Psychiatry, *10*(4), 295–307. https://doi.org/10.1016/S2215-0366(22)00416-8
19. Hor, K., & Taylor, M. (2022). Suicide and schizophrenia: A systematic review of rates and risk factors. Journal of Psychopharmacology, *36*(1), 81–90. https://doi.org/10.1177/02698811211047609
20. Howes, O. D., & Kapur, S. (2021). The dopamine hypothesis of schizophrenia revisited: Mechanistic and clinical implications. Nature Reviews Neuroscience, *22*(7), 436–452. https://doi.org/10.1038/s41583-021-00462-y
21. Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., ... & Leucht, S. (2023). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet, *401*(10378), 1194–1206. https://doi.org/10.1016/S0140-6736(23)00417-X
22. Kane, J. M., Robinson, D. G., Schooler, N. R., Mueser, K. T., Penn, D. L., Rosenheck, R. A., ... & Severe, J. B. (2020). The RAISE early treatment program for first-episode psychosis: A pragmatic, patient-centered, recovery-oriented approach. JAMA Psychiatry, *77*(3), 253–262. https://doi.org/10.1001/jamapsychiatry.2019.3794
23. Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Brunette, M. F., Mueser, K. T., ... & Robinson, D. G. (2021). Long-acting injectable antipsychotics for relapse prevention in schizophrenia: A network meta-analysis. Schizophrenia Bulletin, *47*(5), 1213–1225. https://doi.org/10.1093/schbul/sbab039
24. Koblan, K. S., Kent, J., Hopkins, S. C., Krystal, J. H., Cheng, H., Goldman, R., & Loebel, A. (2020). A non–D2-receptor-binding drug for the treatment of schizophrenia. New England Journal of Medicine, *382*(16), 1497–1506. https://doi.org/10.1056/NEJMoa1911772
25. Lennox, B. R., Palmer-Cooper, E. C., Pollak, T., Hainsworth, J., Marks, J., Jacobson, L., ... & Vincent, A. (2020). Prevalence and clinical characteristics of seronegative autoimmune encephalitis in the psychosis population: A systematic review and meta-analysis. Brain, *143*(3), 1043–1053. https://doi.org/10.1093/brain/awaa008

26. Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., ... & Davis, J. M. (2020). Sixty years of placebo-controlled antipsychotic drug trials: Meta-analysis of 167 studies with 28,102 patients. American Journal of Psychiatry, *177*(9), 861–873. https://doi.org/10.1176/appi.ajp.2020.20030237
27. Linardon, J., Cuijpers, P., Carlbring, P., Messer, M., & Fuller-Tyszkiewicz, M. (2022). The efficacy of app-supported smartphone interventions for mental health problems: A meta-analysis of randomized controlled trials. Journal of Medical Internet Research, *24*(6), Article e35609. https://doi.org/10.2196/35609
28. Marshall, M., & Lockwood, A. (2020). Assertive community treatment for people with severe mental disorders. Cochrane Database of Systematic Reviews, *2020*(12), Article CD001089. https://doi.org/10.1002/14651858.CD001089.pub3
29. Mewton, L., Visontay, R., Chapman, C., Teesson, M., & Sunderland, M. (2022). Comorbid substance use disorders in schizophrenia spectrum disorders: A global prevalence meta-analysis. Psychological Medicine, *52*(7), 1239–1253. https://doi.org/10.1017/S0033291721004770
30. Müller, N., & Schwarz, M. J. (2023). Neuroinflammation in schizophrenia: New treatment targets and biomarker developments. Translational Psychiatry, *13*(1), Article 45. https://doi.org/10.1038/s41398-023-02345-5
31. Myles, N., Myles, H., Xia, S., Large, M., Kisely, S., Galletly, C., & Siskind, D. (2021). Incidence and management of clozapine-induced agranulocytosis: A systematic review. CNS Drugs, *35*(4), 371–386. https://doi.org/10.1007/s40263-021-00802-3
32. Myles, N., et al. (2021). Clozapine-induced agranulocytosis and monitoring: A multidisciplinary protocol. The Lancet Psychiatry.
33. National Institute for Health and Care Excellence. (2022). Psychosis and schizophrenia in adults: Prevention and management (NICE Guideline CG178). https://www.nice.org.uk/guidance/cg178
34. Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., ... & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet Psychiatry, *7*(1), 64–77. https://doi.org/10.1016/S2215-0366(19)30416-X
35. Pillinger, T., et al. (2020). Metabolic effects of antipsychotics: A multidisciplinary approach to monitoring. The Lancet Psychiatry.
36. Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2022). Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: Updated systematic review and meta-analysis. The British Journal of Psychiatry, *220*(4), 228–238. https://doi.org/10.1192/bjp.2021.176
37. Solmi, M., Croatto, G., Piva, G., Rosson, S., Favaro, A., Carvalho, A. F., ... & Correll, C. U. (2022). Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions for negative symptoms in schizophrenia: A systematic review and network meta-analysis. Molecular Psychiatry, *27*(1), 52–61. https://doi.org/10.1038/s41380-021-01114-4
38. Solmi, M., Radua, J., Olivola, M., Croce, E., Soardo, L., Salazar de Pablo, G., ... & Fusar-Poli, P. (2022). Age at onset of mental disorders worldwide: Large-scale meta-analysis of 192 epidemiological studies. Molecular Psychiatry, *27*(1), 281–295. https://doi.org/10.1038/s41380-021-01171-9
39. Takeuchi, H., Fervaha, G., Powell, V., & Remington, G. (2022). Pharmacist-led clozapine monitoring programs: Impact on safety outcomes and adherence. The Journal of Clinical Psychiatry, *83*(2), Article 21m14023. https://doi.org/10.4088/JCP.21m14023
40. Taylor, D., Barnes, T. R. E., & Young, A. H. (2021). The Maudsley prescribing guidelines in psychiatry (14th ed.). Wiley-Blackwell.
41. Taylor, D. M., et al. (2021). The Maudsley prescribing guidelines in psychiatry (14th ed.). Wiley-Blackwell.
42. Tiihonen, J., Tanskanen, A., & Taipale, H. (2022). Real-world adherence and treatment patterns in schizophrenia across Europe and Asia. The Lancet Psychiatry, *9*(2), 117–128. https://doi.org/10.1016/S2215-0366(21)00385-4

43. Tiihonen, J., et al. (2022). Multidisciplinary strategies for treatment-resistant schizophrenia. World Psychiatry.
44. U.S. Food and Drug Administration. (2022). Clozapine REMS (Risk Evaluation and Mitigation Strategy). https://www.clozapinerems.com
45. van Erp, T. G. M., Walton, E., Hibar, D. P., Schmaal, L., Jiang, W., Glahn, D. C., ... & Turner, J. A. (2021). Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 healthy controls via the ENIGMA consortium. Biological Psychiatry, *84*(9), 644–654. https://doi.org/10.1016/j.biopsych.2018.04.023
46. Velligan, D. I., Sajatovic, M., Hatch, A., Kramata, P., & Docherty, J. P. (2021). Medication adherence challenges in schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin, *47*(4), 902–913. https://doi.org/10.1093/schbul/sbaa179
47. World Health Organization. (2021). Comprehensive mental health action plan 2013–2030. WHO. https://www.who.int/publications/i/item/9789240031029
48. World Health Organization. (2022). Schizophrenia. WHO. https://www.who.int/news-room/fact-sheets/detail/schizophrenia
49. Xia, J., Merinder, L. B., & Belgamwar, M. R. (2021). Psychoeducation for schizophrenia. Cochrane Database of Systematic Reviews, *2021*(3), Article CD002831. https://doi.org/10.1002/14651858.CD002831.pub3
50. Yoshimura, R., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., & Nakamura, J. (2021). Brain-derived neurotrophic factor (BDNF) and treatment response in schizophrenia: Systematic review and meta-analysis. Frontiers in Psychiatry, *12*, Article 620135. https://doi.org/10.3389/fpsyt.2021.620135